article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. It explores the monoclonal antibody detection that may work against procathepsin-L (pCTS-L), a pro-inflammatory protein mediator, as the potential remedy.

Protein 263
article thumbnail

Covid-19 induced immune response may damage brain, NINDS study finds

Pharmaceutical Technology

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Team studies immune response, proteins in blood of young adults who develop rare complication after COVID vaccination

Medical Xpress

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

article thumbnail

Study: Infection with common cold coronaviruses can trigger broad cross-immunity against SARS-CoV-2 proteins

Medical Xpress

Researchers at the University Medical Center Hamburg-Eppendorf have demonstrated cross-reactive immune responses to another SARS-CoV-2 protein besides the spike protein.

Protein 98
article thumbnail

Non-canonical proteins as candidate targets for cancer immunotherapy

Medical Xpress

Recently published in Clinical Cancer Research, a study led by Alena Gros, Principal Investigator of the Vall d'Hebron Institute of Oncology's Tumor Immunology and Immunotherapy Group, tested more than 500 peptides (amino acid sequences) derived from non-canonical proteins as candidate tumor antigens that could be recognized by T-cells that activate (..)

Protein 75
article thumbnail

The host immune response in COVID-19 and beyond

pharmaphorum

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

article thumbnail

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

pharmaphorum

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.